Losartan Potassium Tablet, Film Coated
Product Images NDC 87441-053

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 87441-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium 50 mg (8744105301 Losartan Potassium 50 mg)

Label for Losartan Potassium 50 mg tablets, USP, Rx only. The label includes dosing instructions referencing a package insert, storage conditions (20° to 25°C with permitted excursions), and information about repackaging by Unit Dose Solutions, Inc. and distribution by Tuckco Enterprises, LLC. It specifies that each tablet contains 25 mg of Losartan Potassium USP, with space for lot number, expiration date, and quantity.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over study months between Atenolol and Losartan Potassium. The graph shows adjusted risk reduction and statistical significance (p=0.021) with Losartan Potassium having a lower curve than Atenolol throughout the study.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period for Atenolol and Losartan Potassium. The chart shows a gradual increase over time, with Losartan Potassium consistently associated with a lower percentage of patients experiencing stroke events, indicating an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Figure 3 (Losartan Fig3)

A forest plot chart comparing primary endpoint events including stroke in demographic subgroups. It shows event rates and hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol, stratified by age, gender, race, ISH, diabetes, and cardiovascular disease history.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The solid line represents Losartan Potassium, showing a lower event rate compared to the dashed placebo line. The graph includes a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure diagram of Losartan Potassium, a detailed molecular representation showing the arrangement of atoms and bonds within the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.